Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Blockbuster Bubble: What is the Real Trend in R&D Output?

This article was originally published in RPM Report

Executive Summary

The years 1996 and 1997 were terrific for the biopharmaceutical industry, with record numbers of new product approvals. It is now clear, though, that they were outliers from the historic rates of new product flow. That fact has important implications: the products approved in those years are the blockbusters industry is still living on, and they supported massive infrastructure that Big Pharma now needs to shed.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts